Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07785154 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Registry-study of ELZONRIS in Participants With BPDCN

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
The main goal of this registry study is to investigate the effectiveness and safety of tagraxofusp in the treatment of adult participants with BPDCN in the real-world clinical practice setting.
Trial Details
NCT Number NCT07785154
Lead Sponsor Stemline Therapeutics, Inc.
Conditions
(from sponsor)		 Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Related terms Blastic Plasmacytoid Dendritic Cell Neoplasm
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov